

# Mrkt BUZZ, Biosergen: Candidozyma auris on the rise in Europe

Carlsquare Equity Research comments on a recently published article and report concerning increasing incidence rates of Candidozyma auris (formerly known as Candida auris).

[Read the full comment here.](#)

## About Carlsquare

Carlsquare is a global research firm and financial advisor, focusing on M&A, Equity Research and Growth Equity. Carlsquare has 150 employees with deep sector knowledge in all 11 GICS sectors. The senior equity research team has extensive experience about the stock environment and several business sectors. The team produces company research reports, independent valuations and trading notes. The group have offices in Canada, Denmark, France, Germany, Poland, Sweden, United Kingdom and United States. [Read more](#)

## Contacts

### MARKUS AUGUSTSSON

Head of Equity Research

[markus.augustsson@carlsquare.com](mailto:markus.augustsson@carlsquare.com)

+46 (0)76 235 03 20

### NIKLAS ELMHAMMER

Senior Equity Analyst

[niklas.elmhammer@carlsquare.com](mailto:niklas.elmhammer@carlsquare.com)

+46 (0)70 898 39 59

## Attachments

[Mrkt BUZZ, Biosergen: Candidozyma auris on the rise in Europe](#)